WHAT IS CLAIMED IS:

1. A temperature-sensitive thermogelling emulsion delivery system, comprising:

a biodegradable temperature-sensitive aqueous phase polymer solution;

at least one bioactive substance, and

a pharmaceutically acceptable oil phase carrier, said oil carrier embeds said bioactive substance;

wherein

10

5

said oil phase carrier and said temperature-sensitive polymer solution are mixed mutually to form an emulsion, which is a liquid while at a temperature below a lower critical solution temperature (LCST) and transforms into a gel while the temperature of the emulsion is above said lower critical solution temperature (LCST).

15

2. The delivery system as claimed in claim 1, wherein said bioactive substance is embedded in said oil phase carrier by the means of dissolving, solid suspension or water/oil emulsification.

20

- 3. The delivery system as claimed in claim 1, wherein said temperature-sensitive polymer is selected from the group consisting of PEG-PLGA-PEG, PLGA-PEG-PLGA, PEG-PLGA and Poloxamor 407.
- 4. The delivery system as claimed in claim 3, wherein said

PEG-PLGA-PEG is represented as formula (I):

(I)

wherein x is a positive integer between 5 to 20; y is a positive integer between 20 to 40; z is a positive integer between 5 to 20; and R is the substituted linear or branched C_2 to C_{10} alkyl group.

5. The delivery system as claimed in claim 3, wherein said PEG-PLGA is represented as formula (II):

$$H_3C$$
 \leftarrow $\begin{pmatrix} OCH_2CH_2 \end{pmatrix}_n \begin{pmatrix} O & H \\ C & C \end{pmatrix}_x \begin{pmatrix} O & C \\ C & H_2 \end{pmatrix}_y OH$

(II)

wherein n is a positive integer between 5 to 20; x is a positive integer between 20 to 40; and y is a positive integer between 5 to 20.

6. The delivery system as claimed in claim 3, wherein said Poloxamer 407 is represented below:

10

5

15

20

7. The delivery system as claimed in claim 1, wherein said physiologically accepted oil phase carrier is a fatty acid ester.

5

10

15

- 8. The delivery system as claimed in claim 7, wherein said physiologically accepted oil phase carrier is selected from the group consisting of lipiodol, medium chain triglyceride (MCT), soybean oil, sesame oil, castor oil, sunflower oil, mineral oil, vitamin E oil or a mixtire of them.
- 9. The delivery system as claimed in claim 1, wherein at least one bioactive substance is selected from the group consisting of chemical compound, protein, peptide, nucleic acid, polysaccharide, carbohydrate, lipid, glycoprotein and imaging agent.
- 10. The delivery system as claimed in claim 1, which is used for subcutaneous injection, intramuscular injection, intratumor injection or embolism agent.